Macrogenics Stock Today
| MGNX Stock | USD 15.70 0.53 3.27% |
Performance7 of 100
| Odds Of DistressLess than 11
|
MacroGenics is trading at 15.70 as of the 24th of April 2024; that is -3.27 percent decrease since the beginning of the trading day. The stock's open price was 16.23. MacroGenics has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for MacroGenics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2013 | Category Healthcare | Classification Health Care |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.56 M outstanding shares of which 6.45 M shares are now shorted by private and institutional investors with about 3.58 trading days to cover. More on MacroGenics
Moving against MacroGenics Stock
| 0.51 | GILD | Gilead Sciences Earnings Call Tomorrow | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
MacroGenics Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. MacroGenics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding MacroGenics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Scott MD | ||||
| Thematic Idea | Cancer Fighters (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering MacroGenics report their recommendations after researching MacroGenics' financial statements, talking to executives and customers, or listening in on MacroGenics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering MacroGenics. The MacroGenics consensus assessment is calculated by taking the average forecast from all of the analysts covering MacroGenics. | |||||
MacroGenics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to MacroGenics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MacroGenics' financial leverage. It provides some insight into what part of MacroGenics' total assets is financed by creditors.
| |||||
MacroGenics (MGNX) is traded on NASDAQ Exchange in USA. It is located in 9704 Medical Center Drive, Rockville, MD, United States, 20850 and employs 339 people. MacroGenics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.02 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MacroGenics's market, we take the total number of its shares issued and multiply it by MacroGenics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. MacroGenics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.56 M outstanding shares of which 6.45 M shares are now shorted by private and institutional investors with about 3.58 trading days to cover.
MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Check MacroGenics Probability Of Bankruptcy
Ownership AllocationMacroGenics holds a total of 62.56 Million outstanding shares. The majority of MacroGenics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MacroGenics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MacroGenics. Please pay attention to any change in the institutional holdings of MacroGenics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check MacroGenics Ownership Details
MacroGenics Stock Price Odds Analysis
Based on a normal probability distribution, the odds of MacroGenics jumping above the current price in 90 days from now is about 61.63%. The MacroGenics probability density function shows the probability of MacroGenics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4062. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, MacroGenics will likely underperform. Additionally, macroGenics has an alpha of 0.4678, implying that it can generate a 0.47 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of MacroGenics to move above the current price in 90 days from now is about 61.63 (This MacroGenics probability density function shows the probability of MacroGenics Stock to fall within a particular range of prices over 90 days) .
MacroGenics Stock Institutional Holders
Institutional Holdings refers to the ownership stake in MacroGenics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of MacroGenics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MacroGenics' value.| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 1.2 M | |
| Rock Springs Capital Management Lp | 2023-12-31 | 1.2 M | |
| Jpmorgan Chase & Co | 2023-12-31 | 1.1 M | |
| Acadian Asset Management Llc | 2023-12-31 | 1.1 M | |
| Millennium Management Llc | 2023-12-31 | 863 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 833.5 K | |
| Federated Hermes Inc | 2023-12-31 | 803.4 K | |
| Northern Trust Corp | 2023-12-31 | 774.5 K | |
| Renaissance Technologies Corp | 2023-12-31 | 763.5 K | |
| Bellevue Group Ag | 2023-12-31 | 10 M | |
| Blackrock Inc | 2023-12-31 | 6.1 M |
MacroGenics Historical Income Statement
MacroGenics Income Statement is one of the three primary financial statements used for reporting MacroGenics's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of MacroGenics revenue and expense. MacroGenics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, MacroGenics' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 89.7 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 7.1 M in 2024. View More FundamentalsMacroGenics Stock Against Markets
Picking the right benchmark for MacroGenics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in MacroGenics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for MacroGenics is critical whether you are bullish or bearish towards MacroGenics at a given time. Please also check how MacroGenics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in MacroGenics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
MacroGenics Corporate Directors
MacroGenics corporate directors refer to members of a MacroGenics board of directors. The board of directors generally takes responsibility for the MacroGenics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of MacroGenics' board members must vote for the resolution. The MacroGenics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| David Stump | Independent Director | Profile | |
| Jay Siegel | Director | Profile | |
| Scott Jackson | Director | Profile | |
| Matthew Fust | Independent Director | Profile |
How to buy MacroGenics Stock?
Before investing in MacroGenics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in MacroGenics. To buy MacroGenics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of MacroGenics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase MacroGenics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located MacroGenics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased MacroGenics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as MacroGenics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.
Already Invested in MacroGenics?
The danger of trading MacroGenics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of MacroGenics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than MacroGenics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile MacroGenics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether MacroGenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MacroGenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Macrogenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Macrogenics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for MacroGenics Stock analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is MacroGenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MacroGenics. If investors know MacroGenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MacroGenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.949 | Quarterly Revenue Growth (0.85) | Return On Assets (0.36) | Return On Equity (0.06) |
The market value of MacroGenics is measured differently than its book value, which is the value of MacroGenics that is recorded on the company's balance sheet. Investors also form their own opinion of MacroGenics' value that differs from its market value or its book value, called intrinsic value, which is MacroGenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MacroGenics' market value can be influenced by many factors that don't directly affect MacroGenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MacroGenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if MacroGenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MacroGenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.